Pacira BioSciences Total Liabilities

Pacira BioSciences (PCRX) currently reports a total liabilities of $550M as of March 2026. That compares with $790M in the prior-year period — down 29.6% year over year. Use the charts on this page to explore Pacira BioSciences's total liabilities history and peer comparisons.

Pacira BioSciences's total liabilities decreased from $790M to $550M — a 29.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pacira BioSciences reported $550M in total liabilities as of March 2026. That compares with $790M in the prior-year period — down 29.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $550M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pacira BioSciences, and consider following PCRX for alerts when major investors trade the stock.

Pacira BioSciences is classified in the Healthcare sector. On total liabilities, it currently shows $550M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PCRX with unrelated industries.